LifeTech Scientific Corporation
LifeTech Scientific Corporation Fundamental Analysis
LifeTech Scientific Corporation (1302.HK) shows weak financial fundamentals with a PE ratio of 96.54, profit margin of 5.42%, and ROE of 1.98%. The company generates $1.3B in annual revenue with weak year-over-year growth of 2.88%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 39.1/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze 1302.HK's fundamental strength across five key dimensions:
Efficiency Score
Weak1302.HK struggles to generate sufficient returns from assets.
Valuation Score
Moderate1302.HK shows balanced valuation metrics.
Growth Score
Weak1302.HK faces weak or negative growth trends.
Financial Health Score
Excellent1302.HK maintains a strong and stable balance sheet.
Profitability Score
Moderate1302.HK maintains healthy but balanced margins.
Key Financial Metrics
Is 1302.HK Expensive or Cheap?
P/E Ratio
1302.HK trades at 96.54 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, 1302.HK's PEG of -1.65 indicates potential undervaluation.
Price to Book
The market values LifeTech Scientific Corporation at 1.84 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 58.19 times EBITDA. This signals the market has high growth expectations.
How Well Does 1302.HK Make Money?
Net Profit Margin
For every $100 in sales, LifeTech Scientific Corporation keeps $5.42 as profit after all expenses.
Operating Margin
Core operations generate 3.67 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.98 in profit for every $100 of shareholder equity.
ROA
LifeTech Scientific Corporation generates $1.35 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
LifeTech Scientific Corporation generates strong operating cash flow of $618.03M, reflecting robust business health.
Free Cash Flow
LifeTech Scientific Corporation generates strong free cash flow of $580.31M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $0.13 in free cash annually.
FCF Yield
1302.HK converts 8.15% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
96.54
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-1.65
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.84
vs 25 benchmark
P/S Ratio
Price to sales ratio
5.30
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.001
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.59
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.02
vs 25 benchmark
ROA
Return on assets percentage
0.01
vs 25 benchmark
ROCE
Return on capital employed
0.01
vs 25 benchmark
How 1302.HK Stacks Against Its Sector Peers
| Metric | 1302.HK Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 96.54 | 28.54 | Worse (Expensive) |
| ROE | 1.98% | 738.00% | Weak |
| Net Margin | 5.42% | -43982.00% (disorted) | Weak |
| Debt/Equity | 0.00 | 0.34 | Strong (Low Leverage) |
| Current Ratio | 2.59 | 2806.01 | Strong Liquidity |
| ROA | 1.35% | -14624.00% (disorted) | Weak |
1302.HK outperforms its industry in 2 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews LifeTech Scientific Corporation's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
84.27%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
62.73%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
10.52%
Industry Style: Defensive, Growth, Innovation
High Growth